VAERS Reports GN9703

VAERS 2552425

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH BIVALENT)) · Charge GN9703

gering

Staat: PA
Alter: 67,0
Geschlecht: M
Eingang: 06.01.2023
Impfdatum: 11.10.2022
Beginn: 28.10.2022
Tage bis Beginn: 17,0
Dosis: 5
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: ja Erholt: nein

Biopsy Computerised tomogram abnormal Lymphadenopathy Lymphoma Pharyngeal mass Positron emission tomogram abnormal Throat cancer

Symptomtext

Lymph nodes in right side of neck had accute swelling

Weitere VAERSDATA-Felder

Praegender Schweregrund: Biopsy
Hospital-Tage: 3,0
Labordaten: CT Scan (11/16/2022) showed mass growing in throat; Biopsy (1/6/2022) indicated growth was cancerous, PET CT Scan (1/23/2022) indicated cancer in throat and lymph nodes on both sides of neck.
Aktuelle Erkrankungen: None known
Vorgeschichte: Myasthenia Gravis (occular)
Andere Medikamente: Simvasratin 20mg, Pyridostigmine 60mg (4x)
Allergien: None known
Vorherige Impfungen: -

VAERS 2551930

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge Gn9703

gering

Staat: CA
Alter: 78,0
Geschlecht: M
Eingang: 06.01.2023
Impfdatum: 16.10.2022
Beginn: -
Tage bis Beginn: -
Dosis: 4
Route/Site: - / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

COVID-19 Drug ineffective Interchange of vaccine products SARS-CoV-2 test

Symptomtext

COVID 19 Treatment; COVID 19 Treatment; vaccine brand other= Moderna/vaccine administration date=02Nov2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 78-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 16Oct2022 as dose 4 (booster), single (Lot number: Gn9703) at the age of 78 years, in right arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 27Jan2021 as dose 1, single (Batch/Lot number: unknown), in right arm, on 25Feb2021 as dose 2, single (Lot number: 013a21a), in right arm and on 02Nov2021 as dose 3 (booster), single (Lot number: 014f21a), in right arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: AVASTATIN; LISINOPRIL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "vaccine brand other= Moderna/vaccine administration date=02Nov2021". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Negative, notes: negative rapid test; (01Jan2023) Positive, notes: Symptoms resumed and rapid test positive about 10 days after finishing Paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: The patient received other medication in 2 weeks. Patient received Paxlovid for COVID 19 treatment from 18Dec2022 to 22Dec2022. No known allergies reported.

Weitere VAERSDATA-Felder

Praegender Schweregrund: COVID-19
Hospital-Tage: -
Labordaten: Test Name: rapid test; Test Result: Negative ; Comments: negative rapid test; Test Date: 20230101; Test Name: rapid test; Test Result: Positive ; Comments: Symptoms resumed and rapid test positive about 10 days after finishing Paxlovid
Aktuelle Erkrankungen: -
Vorgeschichte: Comments: List of non-encoded Patient Relevant History: Patient Other Relevant History 1: None
Andere Medikamente: AVASTATIN; LISINOPRIL
Allergien: -
Vorherige Impfungen: -